IKT - Inhibikase Therapeutics, Inc.
2.19
0.190 8.676%
Share volume: 161,439
Last Updated: 05-12-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.01%
PREVIOUS CLOSE
CHG
CHG%
$2.00
0.19
0.10%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-15-2023 | 08-14-2023 | 11-14-2023 | 03-27-2024 | 05-15-2024 | 08-14-2024 | 11-14-2024 | 03-27-2025 | |
| Total revenue | 64.521 K | 116.410 K | 79.569 K | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 64.521 K | 116.410 K | 79.569 K | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 80.42% | -31.65% | -100.00% | -100.00% | nan% | nan% | nan% | |||
| Operating expenses | 4.779 M | 6.319 M | 4.848 M | 4.404 M | 4.782 M | 5.051 M | 5.827 M | 12.929 M | |
| Selling general and admin | 1.925 M | 1.783 M | 1.623 M | 1.401 M | 2.031 M | 1.975 M | 1.638 M | 5.735 M | |
| Research and development | 2.854 M | 4.536 M | 3.226 M | 3.003 M | 2.751 M | 3.076 M | 4.190 M | 7.194 M | |
| Total expenses | 4.779 M | 6.319 M | 4.848 M | 4.404 M | 4.782 M | 5.051 M | 5.827 M | 12.929 M | |
| 32.21% | -23.27% | -9.18% | 8.60% | 5.61% | 15.38% | 121.86% | |||
| Operating income | -4.715 M | -6.202 M | -4.769 M | -4.404 M | -4.782 M | -5.051 M | -5.827 M | -12.929 M | |
| Ebit | -4.715 M | -6.202 M | -4.769 M | -4.404 M | -4.782 M | -5.051 M | -5.827 M | -12.929 M | |
| Pretax income | -4.478 M | -5.778 M | -4.595 M | -4.178 M | -4.650 M | -4.960 M | -5.778 M | -12.133 M | |
| 29.04% | -20.47% | -9.08% | 11.29% | 6.67% | 16.50% | 109.98% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -4.478 M | -5.778 M | -4.595 M | -4.178 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| -29.04% | 20.47% | 9.08% | 100.00% | ||||||
| Net income | -4.478 M | -5.778 M | -4.595 M | -4.178 M | -4.650 M | -4.960 M | -5.778 M | -12.133 M | |
| -29.04% | 20.47% | 9.08% | -11.29% | -6.67% | -16.50% | -109.98% |
